Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926180 | 1.00 | PDE4B (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926148 | 1.00 | PDE4B (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926145 | 0.99 | PRKDC (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926144 | 0.99 | PRKDC (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926151 | 0.99 | PRKDC (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926149 | 0.99 | PRKDC (0.34) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL20976228 | 0.97 | PRKDC (0.36) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL20976227 | 0.97 | PRKDC (0.36) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL20976188 | 0.97 | PRKDC (0.36) | PDE4BP2RX4PLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9926167 | 0.97 | P2RX4 (0.35) | PDE4BP2RX4EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10283718-B2 | Charge transporting material, organic electroluminescent element, light emitting device, display device and illumination device | UDC IRELAND LIMITED (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2649080-B1 | INDOLOPHENOXAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | CANON KK (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9515270-B2 | Indolophenoxazine compound and organic light emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9515270-B2 | Indolophenoxazine compound and organic light emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20130228770-A1 | INDOLOPHENOXAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130228770-A1 | INDOLOPHENOXAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-09-05 | — | — | US | disclosed |
| WO-2012077582-A1 | INDOLOPHENOXAZINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10283718-B2 | Charge transporting material, organic electroluminescent element, light emitting device, display device and illumination device | SLC39A11, GNA11, TMEM109 | PDE4B 4846/4885P2RX4 2733/4885PLA2G2A 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.